%u201CThis is another example of how Elanco is becoming a more important part of Eli Lilly,%u201D said William Weldon, Elanco%u2019s vice president of global research and development. Elanco already has operations around the world. With the acquisition of Novartis Animal Health, that reach will be even greater. (Tom Russo / Daily Reporter)
GREENFIELD — Elanco Animal Health solidified itself Tuesday as the rising star of Eli Lilly and Co.
In what Elanco and Lilly officials called one of the most significant moves in the companies’ histories, Lilly announced a $5.4 billion acquisition that will make its Greenfield-based animal health division a global titan in developing and producing foods and medicine for even more species ranging from canines to cattle to catfish.